Share Capital (Tables)
|
12 Months Ended |
Dec. 31, 2017 |
|---|
| Share Capital [Abstract] |
|
| Summary of stock option activities and related information |
| |
|
|
Number of options |
|
|
Weighted average exercise price |
|
|
Weighted average remaining contractual term |
|
|
Aggregate intrinsic-value |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Outstanding at the beginning of the year |
|
|
836,514 |
|
|
$ |
0.63 |
|
|
|
|
|
|
|
|
|
| |
Granted* |
|
|
688,288 |
|
|
$ |
1.09 |
|
|
|
|
|
|
|
|
|
| |
Options forfeited |
|
|
(95,089 |
) |
|
$ |
0.92 |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Outstanding at the end of the year |
|
|
1,429,713 |
|
|
$ |
0.83 |
|
|
$ |
6.29 |
|
|
$ |
240,986 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Exercisable as of December 31 |
|
|
913,617 |
|
|
$ |
0.78 |
|
|
$ |
5.89 |
|
|
$ |
197,977 |
|
| |
(*) |
Include 198,788 options that were granted in connection with the Digiflex acquisition, refer to Note 3 for additional information. |
|
| Summary of options granted outstanding and exercise prices |
| |
|
|
Outstanding |
|
|
Exercisable |
|
| |
Exercise price |
|
Number of options |
|
|
Weighted average remaining contractual life (years) |
|
|
Number of options |
|
|
Weighted average remaining contractual life (years) |
|
| |
* |
|
230,425 |
|
|
5.4 |
|
|
230,425 |
|
|
5.4 |
|
| |
0.45 |
|
|
63,097 |
|
|
|
2.7 |
|
|
|
63,097 |
|
|
|
2.7 |
|
| |
0.92 |
|
|
937,403 |
|
|
|
6.6 |
|
|
|
421,307 |
|
|
|
6.1 |
|
| |
* |
|
|
37,924 |
|
|
|
3.3 |
|
|
|
37,924 |
|
|
|
3.3 |
|
| |
0.03 |
|
|
102,096 |
|
|
|
9.8 |
|
|
|
102,096 |
|
|
|
9.8 |
|
| |
0.34 |
|
|
8,020 |
|
|
|
6.1 |
|
|
|
8,020 |
|
|
|
6.1 |
|
| |
4.72 |
|
|
1,068 |
|
|
|
4.2 |
|
|
|
1,068 |
|
|
|
4.2 |
|
| |
5.05 |
|
|
2,769 |
|
|
|
4.2 |
|
|
|
2,769 |
|
|
|
4.2 |
|
| |
5.73 |
|
|
37,623 |
|
|
|
4.3 |
|
|
|
37,623 |
|
|
|
4.3 |
|
| |
6.23 |
|
|
9,648 |
|
|
|
7 |
|
|
|
9,648 |
|
|
|
7 |
|
| |
|
|
|
1,429,713 |
|
|
|
|
|
|
|
913,617 |
|
|
|
|
|
| |
(*) |
Represents an amount lower than $0.01. |
|
| Summary of stock based compensation |
| |
|
|
Year Ended December 31, |
|
| |
|
|
2017* |
|
|
2016 |
|
|
2015 |
|
| |
|
|
|
|
|
|
|
|
|
|
| |
Cost of revenues |
|
$ |
- |
|
|
$ |
(99 |
) |
|
$ |
107 |
|
| |
Research and Development |
|
|
17,956 |
|
|
|
8,828 |
|
|
|
2,597 |
|
| |
Sales and Marketing |
|
|
9,747 |
|
|
|
7,220 |
|
|
|
839 |
|
| |
General and Administrative |
|
|
108,431
|
|
|
|
36,440 |
|
|
|
5,245 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
$ |
136,134 |
|
|
$ |
52,389 |
|
|
$ |
8,788 |
|
| |
* |
On November 19, 2017 the Company provided an additional exercise period for a few employees. Such modification resulted in recording an additional $54,598 stock based compensation. Such amount is presented within the 2017 stock based compensation |
|
| Summary of outstanding warrants |
| |
Issuance date |
|
Outstanding |
|
|
Exercise price |
|
|
Exercisable through |
| |
2009 |
|
|
117,209 |
|
|
|
(***) |
|
|
Exit event |
| |
2013 |
|
|
59,384 |
|
|
$ |
0.92 |
|
|
2023 |
| |
2013 |
|
|
8,182 |
|
|
$ |
0.92 |
|
|
(*) |
| |
2014 |
|
|
51,096 |
|
|
$ |
1.50 |
|
|
(*) |
| |
2016 |
|
|
7,832 |
|
|
$ |
1.50 |
|
|
(**) |
| |
2016 |
|
|
333 |
|
|
$ |
0.75 |
|
|
(**) |
| |
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
244,036 |
|
|
|
|
|
|
|
| |
(*) |
The earlier of: 5 years from the issuance date or the consummation of Initial Public Offering (“IPO”) or Merger and Acquisition (“M&A”) Transaction. |
| |
(**) |
The earlier of: 2 years from the issuance date or the consummation of IPO or M&A Transaction |
| |
(***) |
Represents an amount lower than $0.01 |
|